Investigating how the MACL-1 breast cancer secretome enhances inflammation and fibroblast activity, suggesting implications for tumor progression.
Tumor-secreted factors reprogram the stromal microenvironment to facilitate cancer progression. This study investigates the effects of the MACL-1 breast cancer cell secretome on CCD19-Lu fibroblasts. Fibroblasts treated with the MACL-1 secretome exhibited increased proliferation, altered morphology, and upregulated expression of vimentin, NFκB, and fibroblast-activating protein, indicative of an inflammatory, activated phenotype. Additionally, elevated mitochondrial superoxide levels and an enrichment of proteases were detected in the secretome, but not in corresponding cell lysates. These findings suggest that the MACL-1 secretome promotes fibroblast activation and inflammation, underscoring its potential role in tumor-stroma interactions and breast cancer progression.
No takes yet. Share an insight, caveat, or question.
Barros et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: